Tetrahydrobiopterin and Cardiovascular Disease

Tetrahydrobiopterin (BH4) is an essential cofactor for the aromatic amino acid hydroxylases, which are essential in the formation of neurotransmitters, and for nitric oxide synthase. It is presently used clinically to treat some forms of phenylketonuria (PKU) that can be ameliorated by BH4 supplementation. Recent evidence supports potential cardiovascular benefits from BH4 replacement for the treatment of hypertension, ischemia-reperfusion injury, and cardiac hypertrophy with chamber remodeling. Such disorders exhibit BH4 depletion because of its oxidation and/or reduced synthesis, which can result in functional uncoupling of nitric oxide synthase (NOS). Uncoupled NOS generates more oxygen free radicals and less nitric oxide, shifting the nitroso–redox balance and having adverse consequences on the cardiovascular system. While previously difficult to use as a treatment because of chemical instability and cost, newer methods to synthesize stable BH4 suggest its novel potential as a therapeutic agent. This review discusses the biochemistry, physiology, and evolving therapeutic potential of BH4 for cardiovascular disease.

[1]  F. Ruschitzka,et al.  Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia , 2007, Heart.

[2]  L. d’Uscio,et al.  Increased vascular biosynthesis of tetrahydrobiopterin in apolipoprotein E-deficient mice. , 2006, American journal of physiology. Heart and circulatory physiology.

[3]  N. Nakanishi,et al.  Delivery of exogenous tetrahydrobiopterin (BH4) to cells of target organs: role of salvage pathway and uptake of its precursor in effective elevation of tissue BH4. , 2005, Molecular genetics and metabolism.

[4]  K. Rockett,et al.  Stoichiometric Relationships Between Endothelial Tetrahydrobiopterin, Endothelial NO Synthase (eNOS) Activity, and eNOS Coupling in Vivo: Insights From Transgenic Mice With Endothelial-Targeted GTP Cyclohydrolase 1 and eNOS Overexpression , 2005, Circulation research.

[5]  Y. Hattori,et al.  Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress , 2005, Journal of hypertension.

[6]  H. Cai,et al.  Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[8]  K. Rockett,et al.  Pivotal Role for Endothelial Tetrahydrobiopterin in Pulmonary Hypertension , 2005, Circulation.

[9]  J. Keaney,et al.  Cytokine-Stimulated GTP Cyclohydrolase I Expression in Endothelial Cells Requires Coordinated Activation of Nuclear Factor-&kgr;B and Stat1/Stat3 , 2005, Circulation research.

[10]  J. Boucher,et al.  Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. , 2004, Free radical biology & medicine.

[11]  N. Alp,et al.  Increased Endothelial Tetrahydrobiopterin Synthesis by Targeted Transgenic GTP-Cyclohydrolase I Overexpression Reduces Endothelial Dysfunction and Atherosclerosis in ApoE-Knockout Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[12]  N. Alp,et al.  Regulation of Endothelial Nitric Oxide Synthase by Tetrahydrobiopterin in Vascular Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[13]  S. Verma,et al.  Tetrahydrobiopterin attenuates homocysteine induced endothelial dysfunction , 2003, Molecular and Cellular Biochemistry.

[14]  E. Werner,et al.  In search of a function for tetrahydrobiopterin in the biosynthesis of nitric oxide , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[15]  S. Kaufman.  Some metabolic relationships between biopterin and folate: Implications for the “methyl trap hypothesis” , 1991, Neurochemical Research.

[16]  H. Hasegawa,et al.  Tetrahydrobiopterin uptake in supplemental administration: elevation of tissue tetrahydrobiopterin in mice following uptake of the exogenously oxidized product 7,8-dihydrobiopterin and subsequent reduction by an anti-folate-sensitive process. , 2004, Journal of pharmacological sciences.

[17]  K. Griendling,et al.  Reactive oxygen species in the vasculature: molecular and cellular mechanisms. , 2003, Hypertension.

[18]  M. Itoh,et al.  cGMP inhibits GTP cyclohydrolase I activity and biosynthesis of tetrahydrobiopterin in human umbilical vein endothelial cells. , 2003, Journal of pharmacological sciences.

[19]  N. Blau,et al.  Critical Role of Interleukin-1&bgr; for Transcriptional Regulation of Endothelial 6-Pyruvoyltetrahydropterin Synthase , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[20]  G. Fink,et al.  Gene Transfer of Human Guanosine 5′-Triphosphate Cyclohydrolase I Restores Vascular Tetrahydrobiopterin Level and Endothelial Function in Low Renin Hypertension , 2003, Circulation.

[21]  K. Rockett,et al.  Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. , 2003, The Journal of clinical investigation.

[22]  D. Harrison,et al.  Interactions of Peroxynitrite, Tetrahydrobiopterin, Ascorbic Acid, and Thiols , 2003, Journal of Biological Chemistry.

[23]  N. Blau,et al.  Possible impact of tetrahydrobiopterin and sepiapterin on endothelial dysfunction. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[24]  Steven M Holland,et al.  Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. , 2003, The Journal of clinical investigation.

[25]  F. Niroomand,et al.  Role of human GTP cyclohydrolase I and its regulatory protein in tetrahydrobiopterin metabolism , 2003, Basic Research in Cardiology.

[26]  Y. Hattori,et al.  HMG-CoA Reductase Inhibitor Increases GTP Cyclohydrolase I mRNA and Tetrahydrobiopterin in Vascular Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[27]  Leslie A. Smith,et al.  Long-Term Vitamin C Treatment Increases Vascular Tetrahydrobiopterin Levels and Nitric Oxide Synthase Activity , 2003, Circulation research.

[28]  K. Noguchi,et al.  Beneficial effect of tetrahydrobiopterin on ischemia-reperfusion injury in isolated perfused rat hearts. , 2002, The Journal of thoracic and cardiovascular surgery.

[29]  N. Alp,et al.  GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. , 2002, Cardiovascular research.

[30]  E. Getzoff,et al.  Distinct Dimer Interaction and Regulation in Nitric-oxide Synthase Types I, II, and III* , 2002, The Journal of Biological Chemistry.

[31]  B. Mitchell,et al.  Impaired Vasodilation and Nitric Oxide Synthase Activity in Glucocorticoid-Induced Hypertension , 2002, Biological research for nursing.

[32]  S. Verma,et al.  Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation. , 2002, The Journal of thoracic and cardiovascular surgery.

[33]  S. Verma,et al.  Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. , 2002, American journal of physiology. Heart and circulatory physiology.

[34]  A. Takeshita,et al.  Tetrahydrobiopterin Improves Impaired Endothelium-Dependent Forearm Vasodilation in Patients with Heart Failure , 2002, Journal of cardiovascular pharmacology.

[35]  K. Chayama,et al.  Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia , 2002, Heart.

[36]  M. Stratford,et al.  Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. , 2002, Free radical biology & medicine.

[37]  A. Kashiwagi,et al.  Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. , 2001, Journal of the American College of Cardiology.

[38]  K. Żwirska-Korczala,et al.  Neopterin measurement in clinical diagnosis , 2001, Journal of clinical pharmacy and therapeutics.

[39]  A. Takeshita,et al.  Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. , 2001, Journal of the American College of Cardiology.

[40]  J. Astern,et al.  Genetic Deficiency of Inducible Nitric Oxide Synthase Reduces Atherosclerosis and Lowers Plasma Lipid Peroxides in Apolipoprotein E–Knockout Mice , 2001, Circulation.

[41]  D. Stuehr,et al.  Oxygen Reduction by Nitric-oxide Synthases* , 2001, The Journal of Biological Chemistry.

[42]  D. Harrison,et al.  Endothelial Regulation of Vasomotion in ApoE-Deficient Mice: Implications for Interactions Between Peroxynitrite and Tetrahydrobiopterin , 2001, Circulation.

[43]  M. Marletta,et al.  Reconstitution of Pterin-free Inducible Nitric-oxide Synthase* , 2001, The Journal of Biological Chemistry.

[44]  E. Werner,et al.  l-Ascorbic Acid Potentiates Endothelial Nitric Oxide Synthesis via a Chemical Stabilization of Tetrahydrobiopterin* , 2001, The Journal of Biological Chemistry.

[45]  A. Dorrance,et al.  Glucocorticoids Inhibit Tetrahydrobiopterin-Dependent Endothelial Function , 2001, Experimental biology and medicine.

[46]  Y. Kiuchi,et al.  Stimulation of tetrahydrobiopterin synthesis induced by insulin: possible involvement of phosphatidylinositol 3-kinase. , 2001, The international journal of biochemistry & cell biology.

[47]  N. Blau,et al.  Systemic Tetrahydrobiopterin (BH4) Levels and Coronary Artery Disease , 2001, Cardiology.

[48]  H. Maegawa,et al.  Oral Administration of Tetrahydrobiopterin Prevents Endothelial Dysfunction and Vascular Oxidative Stress in the Aortas of Insulin-Resistant Rats , 2000, Circulation research.

[49]  E. Werner,et al.  Low-temperature optical absorption spectra suggest a redox role for tetrahydrobiopterin in both steps of nitric oxide synthase catalysis. , 2000, Biochemistry.

[50]  Guoyao Wu,et al.  Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. , 2000, The Biochemical journal.

[51]  O. Hess,et al.  Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. , 2000, Journal of cardiovascular pharmacology.

[52]  Chander Raman,et al.  Tetrahydrobiopterin: An Essential Cofactor of Nitric Oxide Synthase with an Elusive Role , 2000 .

[53]  H. Schmidt,et al.  Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. , 2000, The Biochemical journal.

[54]  T. Imaizumi,et al.  Tetrahydrobiopterin restores endothelial function in long-term smokers. , 2000, Journal of the American College of Cardiology.

[55]  O. Hwang,et al.  Up-regulation of GTP cyclohydrolase I and tetrahydrobiopterin by calcium influx. , 1999, NeuroReport.

[56]  S. Milstien,et al.  Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. , 1999, Biochemical and biophysical research communications.

[57]  H. Schmidt,et al.  Tetrahydrobiopterin Inhibits Monomerization and Is Consumed during Catalysis in Neuronal NO Synthase* , 1999, The Journal of Biological Chemistry.

[58]  J. Tainer,et al.  Mutational Analysis of the Tetrahydrobiopterin-binding Site in Inducible Nitric-oxide Synthase* , 1999, The Journal of Biological Chemistry.

[59]  M. Marletta,et al.  Reactions catalyzed by tetrahydrobiopterin-free nitric oxide synthase. , 1998, Biochemistry.

[60]  N. Blau,et al.  Regulation of 6-pyruvoyltetrahydropterin synthase activity and messenger RNA abundance in human vascular endothelial cells. , 1998, Circulation.

[61]  E. Arikawa,et al.  Insulin-induced vasodilation is dependent on tetrahydrobiopterin synthesis. , 1998, Metabolism: clinical and experimental.

[62]  B. Mayer,et al.  Effects of pH on the structure and function of neuronal nitric oxide synthase. , 1998, The Biochemical journal.

[63]  E. Werner,et al.  Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. , 1998, The Journal of clinical investigation.

[64]  D. Stuehr,et al.  Stopped-flow analysis of CO and NO binding to inducible nitric oxide synthase. , 1998, Biochemistry.

[65]  T. Lüscher,et al.  Atherosclerosis and the two faces of endothelial nitric oxide synthase. , 1998, Circulation.

[66]  S. Milstien,et al.  Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human umbilical vein endothelial cells. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[67]  Y. Hattori,et al.  GTP cyclohydrolase I mRNA induction and tetrahydrobiopterin synthesis in human endothelial cells. , 1997, Biochimica et biophysica acta.

[68]  T. Rabelink,et al.  Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. , 1997, Biochemical and biophysical research communications.

[69]  P. Ortiz de Montellano,et al.  Characterization of human liver inducible nitric oxide synthase expressed in Escherichia coli. , 1997, Archives of biochemistry and biophysics.

[70]  F. Raushel,et al.  The Ferrous-dioxy Complex of Neuronal Nitric Oxide Synthase , 1997, The Journal of Biological Chemistry.

[71]  E. Werner,et al.  Tetrahydrobiopterin binding to macrophage inducible nitric oxide synthase: heme spin shift and dimer stabilization by the potent pterin antagonist 4-amino-tetrahydrobiopterin. , 1997, Biochemistry.

[72]  S. Milstien,et al.  Tetrahydrobiopterin, nitric oxide and regulation of cerebral arterial tone , 1997, Progress in Neurobiology.

[73]  D. Rousseau,et al.  Interactions between substrate analogues and heme ligands in nitric oxide synthase. , 1997, Biochemistry.

[74]  G. Pieper.  Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. , 1997, Journal of cardiovascular pharmacology.

[75]  D. Stuehr.  Structure-function aspects in the nitric oxide synthases. , 1997, Annual review of pharmacology and toxicology.

[76]  J. Kastelein,et al.  Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. , 1997, The Journal of clinical investigation.

[77]  H. Schmidt,et al.  No .NO from NO synthase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Powell,et al.  Smoking impairs the activity of endothelial nitric oxide synthase in saphenous vein. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[79]  T. Scott‐Burden.  Regulation of nitric oxide production by tetrahydrobiopterin. , 1995, Circulation.

[80]  E. Werner,et al.  The pteridine binding site of brain nitric oxide synthase. Tetrahydrobiopterin binding kinetics, specificity, and allosteric interaction with the substrate domain. , 1994, The Journal of biological chemistry.

[81]  S. Milstien,et al.  Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. , 1994, The Journal of clinical investigation.

[82]  S Moncada,et al.  Nitric oxide synthases in mammals. , 1994, The Biochemical journal.

[83]  D. Stuehr,et al.  Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[84]  M. Marletta,et al.  Nitric oxide synthase structure and mechanism. , 1993, The Journal of biological chemistry.

[85]  E. Werner,et al.  Tetrahydrobiopterin and Cytokines , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[86]  N. Sakai,et al.  Tetrahydrobiopterin is required for cytokine-induced nitric oxide production in a murine macrophage cell line (RAW 264). , 1993, Molecular pharmacology.

[87]  S. Gross,et al.  Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. , 1992, The Journal of biological chemistry.

[88]  D. Petrylak,et al.  Interleukin‐2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers , 1989, Cancer.

[89]  R. Cotton,et al.  Biochemical Defect of the hph‐1 Mouse Mutant Is a Deficiency in GTP‐Cyclohydrolase Activity , 1988, Journal of Neurochemistry.

[90]  G. K. Smith,et al.  Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin. , 1985, Annual review of biochemistry.

[91]  M. Edelstein,et al.  Biosynthesis of tetrahydrobiopterin in the presence of dihydrofolate reductase inhibitors. , 1983, Molecular pharmacology.

[92]  M. Edelstein,et al.  Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[93]  O. H. Viveros,et al.  Biopterin cofactor biosynthesis: independent regulation of GTP cyclohydrolase in adrenal medulla and cortex. , 1981, Science.

[94]  W. Lovenberg,et al.  Further studies on tryptophan hydroxylase in rat brainstem and beef pineal. , 1969, Biochemical pharmacology.

[95]  S. Kaufman,et al.  Characteristics of the hepatic phenylalanine-hydroxylating system in newborn rats. , 1965, The Journal of biological chemistry.

[96]  S. Kaufman.  THE STRUCTURE OF THE PHENYLALANINE-HYDROXYLATION COFACTOR. , 1962, Proceedings of the National Academy of Sciences of the United States of America.